Austin Neurology & Neurosciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Neurology & Neurological Sciences.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Neurology & Neurological Sciences. Austin Neurology & Neurosciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of neurology & neurosciences.
Austin Neurology & Neurosciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Austin Neurology & Neurosciences is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Neurology & Neurological Sciences.
The journal aims to promote research communications and provide a forum for doctors, researchers, physicians and healthcare professionals to find most recent advances in all areas of Neurology & Neurological Sciences. Austin Neurology & Neurosciences accepts original research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of neurology & neurosciences.
Austin Neurology & Neurosciences strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing, mutual promotion of multidisciplinary science.
Quantitative trait loci (QTL) analysis and its applications in plant breedingPGS
Abstract
Many agriculturally important traits such as grain yield, protein content and relative disease resistance are controlled by many genes and are known as quantitative traits (also polygenic or complex traits). A quantitative trait depends on the cumulative actions of many genes and the environment. The genomic regions that contain genes associated with a quantitative trait are known as quantitative trait loci (QTLs). Thus, a QTL could be defined as a genomic region responsible for a part of the observed phenotypic variation for a quantitative trait. A QTL can be a single gene or a cluster of linked genes that affect the trait. The effects of individual QTLs may differ from each other and change from environment to environment. The genetics of a quantitative trait can often be deduced from the statistical analysis of several segregating populations. Recently, by using molecular markers, it is feasible to analyze quantitative traits and identify individual QTLs or genes controlling the traits of interest in breeding programs.
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010TigerTox
Historical and current perspectives on genetic toxicology, with commentary and slides on assay predictivity and shortcomings, regulatory guidance, and high-throughput screens to enhance preclinical drug safety.
Antibiogram and Genotypic Analysis using 16S rDNA after Biofield Treatment on...albertdivis
The aim of this study was to evaluate the effect of Mr. Trivedi’s biofield energy treatment on M. morganii in the lyophilized as well as revived state for antimicrobial susceptibility pattern, biochemical characteristics, biotype number and genotype.
MicroRNA-Disease Predictions Based On Genomic Dataijtsrd
Gene Ontology is a structured library of concepts related with one or more gene products through a process called annotation. Association Rules that discovers biologically relevant and corresponding associations. In the existing system, they used Gene Ontology-based Weighted Association Rules for extracting annotated datasets. We here adapt the MOAL algorithm to mine cross-ontology association rules. Cross ontology rules to manipulate the Protein values from three sub ontologys for identifying the gene attacked disease. It focused on intrinsic and extrinsic values. The Co-Regulatory modules between microRNA, Transcription Factor and gene on function level with multiple genomic data. The regulations are compared with the help of integration technique. Iterative Multiplicative Updating Algorithm is used in our project to solve the optimization module function for the above interactions. Comparing the regulatory modules and protein value for gene and generating Bayesian rose tree for the efficiency of our result. Ajitha. C | DivyaLakshmi. K | Jothi Jayashree. M"MicroRNA-Disease Predictions Based On Genomic Data" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-3 , April 2018, URL: http://www.ijtsrd.com/papers/ijtsrd11386.pdf http://www.ijtsrd.com/computer-science/data-miining/11386/microrna-disease-predictions-based-on-genomic-data/ajitha-c
Circulating Biomarkers for Alzheimer's Disease: Neurodegenerative Disorders ...QIAGEN
Alzheimer's disease (AD) is a complex neurodegenerative disorder. Circulating miRNAs hold great promise in the discovery of non-invasive and novel biomarkers for AD diagnosis and prognosis. This slideshow presents the role of miRNAs in AD and details current progress in biomarker discovery. Various tools for pathway-focused and genome-wide miRNA expression profiling, miRNA functional studies and target identification are also included.
Quantitative trait loci (QTL) analysis and its applications in plant breedingPGS
Abstract
Many agriculturally important traits such as grain yield, protein content and relative disease resistance are controlled by many genes and are known as quantitative traits (also polygenic or complex traits). A quantitative trait depends on the cumulative actions of many genes and the environment. The genomic regions that contain genes associated with a quantitative trait are known as quantitative trait loci (QTLs). Thus, a QTL could be defined as a genomic region responsible for a part of the observed phenotypic variation for a quantitative trait. A QTL can be a single gene or a cluster of linked genes that affect the trait. The effects of individual QTLs may differ from each other and change from environment to environment. The genetics of a quantitative trait can often be deduced from the statistical analysis of several segregating populations. Recently, by using molecular markers, it is feasible to analyze quantitative traits and identify individual QTLs or genes controlling the traits of interest in breeding programs.
Fundamentals Of Genetic Toxicology In The Pharmaceutical Industry Sept 2010TigerTox
Historical and current perspectives on genetic toxicology, with commentary and slides on assay predictivity and shortcomings, regulatory guidance, and high-throughput screens to enhance preclinical drug safety.
Antibiogram and Genotypic Analysis using 16S rDNA after Biofield Treatment on...albertdivis
The aim of this study was to evaluate the effect of Mr. Trivedi’s biofield energy treatment on M. morganii in the lyophilized as well as revived state for antimicrobial susceptibility pattern, biochemical characteristics, biotype number and genotype.
MicroRNA-Disease Predictions Based On Genomic Dataijtsrd
Gene Ontology is a structured library of concepts related with one or more gene products through a process called annotation. Association Rules that discovers biologically relevant and corresponding associations. In the existing system, they used Gene Ontology-based Weighted Association Rules for extracting annotated datasets. We here adapt the MOAL algorithm to mine cross-ontology association rules. Cross ontology rules to manipulate the Protein values from three sub ontologys for identifying the gene attacked disease. It focused on intrinsic and extrinsic values. The Co-Regulatory modules between microRNA, Transcription Factor and gene on function level with multiple genomic data. The regulations are compared with the help of integration technique. Iterative Multiplicative Updating Algorithm is used in our project to solve the optimization module function for the above interactions. Comparing the regulatory modules and protein value for gene and generating Bayesian rose tree for the efficiency of our result. Ajitha. C | DivyaLakshmi. K | Jothi Jayashree. M"MicroRNA-Disease Predictions Based On Genomic Data" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-3 , April 2018, URL: http://www.ijtsrd.com/papers/ijtsrd11386.pdf http://www.ijtsrd.com/computer-science/data-miining/11386/microrna-disease-predictions-based-on-genomic-data/ajitha-c
Circulating Biomarkers for Alzheimer's Disease: Neurodegenerative Disorders ...QIAGEN
Alzheimer's disease (AD) is a complex neurodegenerative disorder. Circulating miRNAs hold great promise in the discovery of non-invasive and novel biomarkers for AD diagnosis and prognosis. This slideshow presents the role of miRNAs in AD and details current progress in biomarker discovery. Various tools for pathway-focused and genome-wide miRNA expression profiling, miRNA functional studies and target identification are also included.
Pharmacogenomic Prediction of Antracycline-induced CardiotoxicityGolden Helix
Cancer remains a leading cause of morbidity and mortality world-wide. It is estimated that at least 14.1 million people are diagnosed with cancer every year and it currently accounts for at least 15% of all human deaths. Recent advances in modern medicine have significantly improved the cure rates over the last few decades, but an increase in adverse drug reactions (ADRs) has been seen with the increased intensity of treatment. Anthracycline-based cancer treatments are highly effective for many types of cancers, especially childhood malignancies and breast cancer and have significantly improved the 5 – year survival rates of many cancers from 30% to greater than 80%.
However, the use of Anthracycline-based cancer treatments is being questioned due to a highly individualized ADR, cardiac toxicity. In order for Anthracycline-based cancer treatments to remain on the market as highly effective therapies for many severely ill patients, it is imperative to identify the inherited genetic predispositions causing these ADRs, build an ADR prediction algorithm and implement this in a cost effective pharmacogenetic ADR prevention program. The ultimate goal is to tailor the right treatment to the right patients and improve the safety of these medications currently on the market.
The Canadian Pharmacogenomics Network for Drug Safety (CPNDS), recently discovered a novel gene (RARG) responsible for cardiomyopathy and congestive heart failure in cancer survivors and has developed clinical practice recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity in children after cancer treatment.
Join us as Dr. Folefac Aminkeng, presents the CPNDS’ important research efforts focused on understanding the role of genes in ADRs and developing drug safety solutions for cancer patients, initiatives which are critical to improving long-term survival outcomes.
Los días 11 y 12 de diciembre de 2014, la Fundación Ramón Areces celebró el Simposio Internacional 'Neuropatías periféricas hereditarias. Desde la biología a la terapéutica' en colaboración con CIBERER-ISCIII y el Centro de Investigación Príncipe Felipe. El tipo más común de estas patologías es la enfermedad de Charcot-Marie-Tooth, un trastorno neuromuscular hereditario con una prevalencia estimada de 17-40 afectados por 100.000 habitantes. Durante estos dos días, investigadores mostraron sus avances en la mejora del diagnóstico y el tratamiento y, por ende, de la aproximación clínica y la calidad de vida de las personas afectadas por estas patologías.
Manteia non confidential-presentation 2003-09Pascal Mayer
A non confidential corporate presentation of "Manteia Predictive Médicine" as of September 2003. Présents DNA colony sequencing resutls, instrument, DNA preparation for genotyping.
Investigating Shared Additive Genetic Variation for Alcohol DependenceGolden Helix
Molecular genetic research has supported the use of a multivariate phenotype representing alcohol dependence in studies of genetic association. One recent study found that additive genetic effects on Diagnostic and Statistical Manual of Mental Disorder version four (DSM-IV) alcohol dependence criteria overlap, describing a common pathway model that consists of a single latent variable representing alcohol dependence (Palmer et al. 2015). Common single nucleotide polymorphisms (SNPs) explained 31% of variance in this latent factor. However, these findings were conducted using a sample of European Americans and minimal research exists to provide insight into whether this finding is consistent in a population of African descent. Using a large sample of individuals from European and African ancestry, we investigated the extent to which additive genetic variance tagged by common SNPs explain variation in alcohol dependence and whether these markers are shared across the two populations.
DNA Methylation: An Essential Element in Epigenetics Facts and TechnologiesQIAGEN
Check out this slide deck from Dr. Thorsten Singer and Dr. Ralf Peist to learn about DNA methylation in epigenetics, from its significance in cancer to strategies for studying it.
Adjusting OpenMP PageRank : SHORT REPORT / NOTESSubhajit Sahu
For massive graphs that fit in RAM, but not in GPU memory, it is possible to take
advantage of a shared memory system with multiple CPUs, each with multiple cores, to
accelerate pagerank computation. If the NUMA architecture of the system is properly taken
into account with good vertex partitioning, the speedup can be significant. To take steps in
this direction, experiments are conducted to implement pagerank in OpenMP using two
different approaches, uniform and hybrid. The uniform approach runs all primitives required
for pagerank in OpenMP mode (with multiple threads). On the other hand, the hybrid
approach runs certain primitives in sequential mode (i.e., sumAt, multiply).
Chatty Kathy - UNC Bootcamp Final Project Presentation - Final Version - 5.23...John Andrews
SlideShare Description for "Chatty Kathy - UNC Bootcamp Final Project Presentation"
Title: Chatty Kathy: Enhancing Physical Activity Among Older Adults
Description:
Discover how Chatty Kathy, an innovative project developed at the UNC Bootcamp, aims to tackle the challenge of low physical activity among older adults. Our AI-driven solution uses peer interaction to boost and sustain exercise levels, significantly improving health outcomes. This presentation covers our problem statement, the rationale behind Chatty Kathy, synthetic data and persona creation, model performance metrics, a visual demonstration of the project, and potential future developments. Join us for an insightful Q&A session to explore the potential of this groundbreaking project.
Project Team: Jay Requarth, Jana Avery, John Andrews, Dr. Dick Davis II, Nee Buntoum, Nam Yeongjin & Mat Nicholas
Enhanced Enterprise Intelligence with your personal AI Data Copilot.pdfGetInData
Recently we have observed the rise of open-source Large Language Models (LLMs) that are community-driven or developed by the AI market leaders, such as Meta (Llama3), Databricks (DBRX) and Snowflake (Arctic). On the other hand, there is a growth in interest in specialized, carefully fine-tuned yet relatively small models that can efficiently assist programmers in day-to-day tasks. Finally, Retrieval-Augmented Generation (RAG) architectures have gained a lot of traction as the preferred approach for LLMs context and prompt augmentation for building conversational SQL data copilots, code copilots and chatbots.
In this presentation, we will show how we built upon these three concepts a robust Data Copilot that can help to democratize access to company data assets and boost performance of everyone working with data platforms.
Why do we need yet another (open-source ) Copilot?
How can we build one?
Architecture and evaluation
Unleashing the Power of Data_ Choosing a Trusted Analytics Platform.pdfEnterprise Wired
In this guide, we'll explore the key considerations and features to look for when choosing a Trusted analytics platform that meets your organization's needs and delivers actionable intelligence you can trust.
1. Qike Li, A. Grant Schissler, Vincent Gardeux, Ikbel Achour, Colleen Kenost,
Joanne Berghout, Haiquan Li, Hao Helen Zhang, Yves A. Lussier
N-of-1-pathways MixEnrich: advancing precision
medicine via single-subject analysis in discovering
dynamic changes of transcriptomes
2. Outline
• Background
• Methods: N-of-1-pathways MixEnrich
• Results:
• Simulation Study
• Validation Case Study
• Limitations
• Take home message
We developed a new and effective method to identify
dysregulated pathways within a single patient.
3. Problem statement
Population
Case Control
Average / Common
Gene signature / pathway signature
Control / Case
Paired Samples
Individual
Common
signature
Individual
signature
Transcriptome
Analysis Transcriptome
Analysis
DEG+Enrichment1
GSEA2
1Beißbarth, T. and Speed, T. Bioinformatics 2004; 2Subramanian A. et. al PNAS 2005
5. Bridging the GAP
Dynamic mRNA Changes
Control Case
Methods developed so far
• Focus on static transcriptome profile
• Dynamic changes of transcriptomes
Individual
Pathway dysregulation
6. Bridging the GAP
N-of-1-pathways Wilcoxon1
N-of-1-pathways MD2
Deviation from EqualityMethods developed so far
• Focus on static transcriptome profile
• Dynamic changes of transcriptomes
1Gardeux, V., …, Lussier, Y., JAMIA 2013; 2Schissler, A., …, Lussier, Y., Bioinformatics 2015
Control (Log2 Expression)
Sample 2
Sample1
Case(Log2Expression)
7. Bridging the GAP
Methods developed so far
• Focus on static transcriptome profile
• Dynamic changes of transcriptomes
• Ignore the background noise
Deviation from Equality
1Gardeux, V., …, Lussier, Y., JAMIA 2013; 2Schissler, A., …, Lussier, Y., Bioinformatics 2015
Control (Log2 Expression)
Sample 2
Sample1
Case(Log2Expression)
N-of-1-pathways Wilcoxon1
N-of-1-pathways MD2
8. Bridging the GAP
Methods developed so far
• Focus on static transcriptome profile
• Dynamic changes of transcriptomes
• Ignore the background noise
• Unidirectional dynamic change
Control (Log2 Expression)
Sample 2
Sample1
Case(Log2Expression)
Deviation from Equality
N-of-1-pathways Wilcoxon1
N-of-1-pathways MD2
9. Bridging the GAP
Our Approach
A competitive model to discover
uni- and bi-directional dysregulated
pathways
Baseline Case
Dynamic mRNA Changes
Individual
10. Bridging the GAP
Our Approach
A competitive model to discover
uni- and bi-directional dysregulated
pathways
Our Method
Mixture model clustering
followed by gene-set
enrichment test
(MixEnrich)
Baseline Case
Dynamic mRNA Changes
Individual
11. Outline
• Background
• Methods: N-of-1-pathways MixEnrich
• Results:
• Simulation Study
• Validation Case Study
• Limitations
• Take home message
We developed a new and effective method to identify
dysregulated pathways within a single patient.
14. DEG Discovery: Mixture Model
• The cluster membership of each genei is a latent variable that follows Bernoulli
distribution.
15. DEG Discovery: Mixture Model
• The cluster membership of each genei is a latent variable that follows Bernoulli
distribution.
• Given the cluster membership, the |log2FC| of genei follows the following distribution,
16. DEG Discovery: Mixture Model
• The cluster membership of each genei is a latent variable that follows Bernoulli
distribution.
• Given the cluster membership, the |log2FC| of genei follows the following distribution,
• The likelihood that a genei belongs one cluster or the other is assessed by the
posterior probability using Bayes rules.
18. Gene Set Enrichment
Contingency table for Fisher’s Exact Test
dysregulated genes unaltered genes
genes in target pathway d M – d
genes not in target pathway D - d N - M - D + d
19. Simulation Parameters
Parameter Description of the parameter Values tested
p.S Number of mRNAs randomly chosen in the target pathway {5, 10, [15, 490] by step 25, 500}
p.dPct Percentage of dysregulated mRNAs in the target pathway {(0, 1] by step 0.05}
p.FC Fold change of mRNAs in the target pathway {1.3, 1.5, 2}
p.upPct Percentage of up-regulated mRNAs among dysregulated
mRNAs in the target pathways
{0, 0.1, 0.2, 0.3, 0.4, 0.5}
bg.FC Fold change of dysregulated background mRNAs {0, 1.3, 1.5, 2}
bg.dPct Percentage of dysregulated mRNAs as noise in the
background
{0, 0.01, 0.05, 0.1, 0.2}
• 107,640 scenarios of pathway dysregulation were investigated
20. Outline
• Background
• Methods: N-of-1-pathways MixEnrich
• Results:
• Simulation Study
• Validation Case Study
• Limitations
• Take home message
We developed a new and effective method to identify
dysregulated pathways within a single patient.
26. Outline
• Background
• Methods: N-of-1-pathways MixEnrich
• Results:
• Simulation Study
• Validation Case Study (matched tumor and normal samples
of 45 head and neck cancer patients1)
• Limitations
• Take home message
We developed a new and effective method to identify
dysregulated pathways within a single patient.
1Downloaded from TCGA
27. Study design
45 head and neck cancer patients
30 patients
for building cohort-
expectation standard using
DESeq1+Enrichment
15 patients
for evaluating the performance
of the methods
1Anders, S, and Huber, W. Genome biology 11.10 (2010): 1.
Run Single-subject
methods on each patient
Randomly sample 50
distinct subsets
29. Outline
• Background
• Methods: N-of-1-pathways MixEnrich
• Results:
• Simulation Study
• Validation Case Study
• Limitations
• Take home message
We developed a new and effective method to identify
dysregulated pathways within a single patient.
33. Towards Precision Medicine
Individual
Genetic Makeup
N-of-1-pathways MixEnrich:
Personal Transcriptome Profile
Same Phenotype
Trait or Disease
Personalized drug responses
Personalized disease mechanism
34. Towards Precision Medicine
Individual
Genetic Makeup
N-of-1-pathways MixEnrich:
Personal Transcriptome Profile
Same Phenotype
Trait or Disease
Personalized drug responses
Personalized disease mechanism
Rare diseases
35. Limitations
• Expectation Maximization (EM) algorithm is guaranteed to
converge to global optimum
• Future study: Nonparametric clustering or Ensemble clustering
• Not suitable for testing a small panel of genes (e.g. # genes <
200).
37. N-of-1-pathways MixEnrich Team & Acknowledgements
Ikbel Achour, PhD
Haiquan Li, PhD
Vincent Gardeux, PhD
Joanne Berghout, PhD
Yves A. Lussier, MD
Qike Li, MS A. Grant Schissler, MS Colleen Kenost, EdD
@lussiergroup
@UA_CB2
#PrecisionMedicine
Helen Zhang, PhD
Acknowledgements: This study was supported in part by The University of Arizona Cancer
Center, The University of Arizona BIO5 Institute, The University of Arizona Center for Biomedical
Informatics and Biostatistics, and the University of Arizona Health Sciences Center.
- That’s precisely what we are trying to accomplish with our method—N-of-1-pathways MixEnrich. It’s a single-subject methodto discover the dynamic changes of transcriptomes.
- This presentation highlights the main ideas and results from our proceedings paper.
- Our group specialize in translational medicine, we focus on translating clinical and genomic big data to the realm of precision medicine.
To achieve precision medicine, not only the common signature need to discovered but also the individual signature … the patient-specific signature. This necessitates focusing our analyses on the patient of interest, we define this type of analysis as single-subject analysis.
Building on that, we said why not use two samples from one patient, and that allows us to look at dynamic changes of transcriptomes. And the samples you might look at could be in the application like taking a sample before treatment and a sample after treatment. Or could be something like tumor and non-tumor. So what is it you gain from this? Instead of just seeing a over- or under- expression of a single sample, we actually get to see pathway dysregulations.
N-of-1-pathways Wilcxon and N-of-1 pahtways MD are two methods our group developed for this purpose. Pathways because of the gene-set, and n-of-1 because of the single-subject. These two methods determines if a pathway of interest is dysregulated or not by looking at the expression in both case and control samples. In this illustrative figure to the right, each dot represents a gene, and if you look at the We are looking at the deviation of a pathway from equal expressiondiagonal line, that’s gonna be equal expression in the two sampels.. In this case, the pathway is probably down-regulated in case sample.
These two methods worked well in several applications such as lung cancer, breast cancer, and predicting viral response. But they have two major problems.
First, they ignore the background noise. Since these two methods define dysregulation only based on the information of the pathway under study, in the cases when the two samples are not properly normalized
or maybe a cancer genome that acquired a large amount of passenger mutations, a pathway may be identified as dysregulated merely due to the improper normalization or the presence of passenger mutations. This increases the false positive rates of the two methods.
Secondly, these two methods fail when a pathway has some up-regulated genes and some down-regulated genes. Such as the pathway in this figure. There are fair amount of dysregulated genes in the pathway, but not dysregulated in the same direction. In this case, Wilcoxon or MD won’t callthis pathway as dysregulated, because, on average, this pathway don’t deviate from equal expression. So, this makes the two method less powerful.
To improve on these two aspects, we developed a new method n-of-1-pahtways MixEnrich. It is a competitive model in the sense it defines pathway dysregulation relative to the background.
Also it detects both unidirectional dysregulation and bi-directional dysregulation of pathways.
MixEnrich is a two-step approach, it first identifies all dysregulated genes in the transcriptome and then it performs a gene-set Enrichment test to find the pathways that are enriched with dysregulated genes.
For a patient of interest, we collect two transcriptome samples, for example a healthy tissue and a tumor tissue.
With the two transcriptomes, we compute the absolute value of log fold change for each gene, based on which we cluster all genes in two classes: Unaltered genes and Dysregulated genes. The way the mixture model clustering works is as follows
We model the membership of each gene by a latent variable. In the case of two clusters, this latent variable follows Bernoulli distribution, and the sum of probabilities of a gene belongs each cluster is 1.
If we knew the cluster membership of all the genes, then we can estimate the parameters of the two distriubitons
To evaluate our method, we conducted simulation study, in which over 100 thousand scenarios of pathway dysregulation were investigated. We included six simulation parameters. By varying the four pathway parameters, we generated a various types of dysregulated pathways. On top of that, we included two background parameters to generate a number of scenarios for background noise.
In the simulation study, we focused on the receiver operating characteristic curves – ROC curves. The ROC curve evaluates True positive rate and false positive rate at the same time. A large area under the ROC curve indicates a satisfying performance: low false postive rate and high power.
In the simulation study, we focused on the receiver operating characteristic curves – ROC curves. The ROC curve evaluates True positive rate and false positive rate at the same time. A large area under the ROC curve indicates a satisfying performance: low false postive rate and high power.
The panel of the right hand side provides an overall performance comparison of the three single-subject methods. Apparently. The general performance of MixEnrich is better than the other two methods. Further, we’d like to know how each simulation parameter affects the method performance.
Personalized drug responses
Personalized disease mechanisms
Rare diseases
Personalized drug responses
Personalized disease mechanisms
Rare diseases
Personalized drug responses
Personalized disease mechanisms
Rare diseases
Personalized drug responses
Personalized disease mechanisms
Rare diseases
Intrumental Prior work…. MixEnrich builds upon two main ideas inspired by prior work. First, the cohort-based method, DEG identification followed by gene-set enrichment test, has been widely used and shown to be invaluable in gene-set analysis. However, this cohort based method is not applicable in single-subject analysis due to the lack of replicates. We want to know if we can bring the framework of DEG+Enrichment to single-subject analyses. To do this, essentially we just need to identify the genes that are likely to be dysregulated from a pair of transcriptomes, and then the follwing enrichment test is gonna be the same as it is used in cohort-based method. Our approach of discovering dysregulated genes was inspired by the work of Piccolo et al., in which they use mixture models to cluster genes in a single transcriptome to two class: active and inactive genes. We said, if we can cluster the dynamic changes transcriptomes into two classes: dysreguled genes and unaltered genes, then the whole framework of DEG+Enrichment can be applied in single-subject analysis.